Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Allon Therapeutics Inc NPCUF

Healthcare Biotechnology
Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).


GREY:NPCUF - Post by User

Allon Therapeutics Inc > Biggest Beneficiary of Trump Election at <1.0x BV....
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by CBalardoon Jan 08, 2017 2:36pm
173 Views
Post# 25680761

RE:RE:RE:RE:Biggest Beneficiary of Trump Election at <1.0x BV....

RE:RE:RE:RE:Biggest Beneficiary of Trump Election at <1.0x BV....Who cares about BNN, fonds de solidarit ,Quebec investments,and desjardins, all wanted shares. Our market cap has gone up,but knowing that I know these three companies have done the math and see the upside potential of long term growth in this new structured company. Yes may go down or up but this company is so backlogged right now I see way more write offs in restructure expenses and income pouring for upswing in stock price ,also they stand to make an extra 35%> with conversion from US to Canadian dollar. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities